Growth momentum Patient Square Capital is expanding its portfolio through substantial recent acquisitions and new investments, including a $2.6B Premier Inc deal and stakes in Allogene Therapeutics, signaling readiness for additional high-value healthcare investments and co-investment opportunities.

Strategic hires The appointment of Timothy P. Walbert as Senior Advisor and the firm’s ongoing health care focus indicate a strengthened leadership network and advisory capacity, suggesting potential for partnerships, co-investments, and access to senior industry expertise for portfolio companies.

High-value deals Recent close of a $190M Series B in Osanni Bio and a major Paradigm acquisition highlight Patient Square’s willingness to deploy capital across growth-stage biopharma and healthcare services, presenting opportunities to align with both growth-stage rounds and strategic exits.

Broad tech footprint Utilizing a diverse tech stack and digital tools (Adobe Experience Cloud, Zendesk, Shopify, DocuSign, among others) suggests a capability to modernize portfolio company customer experiences, patient engagement platforms, and vendor/partner ecosystems.

Revenue and reach With assets under management around $19B and revenue in the multi-hundred million range, the firm has substantial scale and buyer power to pursue large healthcare IT, services, and therapeutics opportunities, making it a strong potential partner for vendors targeting PE-backed buyers.